Guardant Health announced that its Guardant Reveal tissue‑free liquid biopsy test now includes late‑stage therapy response monitoring for patients with solid tumors, extending the test’s capabilities beyond minimal residual disease detection.
The expanded test tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels. Results are available in just seven days, eliminating the need for a tissue sample and allowing oncologists to adjust treatment plans earlier.
Clinical validation supports the new use. A study published in The Journal of Liquid Biopsy showed that Guardant Reveal can predict long‑term benefit up to 18 months earlier than standard imaging. The RADIOHEAD study, a large trial focused on immune‑checkpoint inhibitor response, demonstrated that the test detected responses up to five months before imaging and that decreases in tumor fraction correlated with improved outcomes.
Strategically, the expansion adds a new revenue stream to Guardant’s precision oncology portfolio and reinforces its Infinity platform moat. By offering a tissue‑free, rapid, and broadly applicable monitoring solution, Guardant positions itself to capture a larger share of the growing market for real‑time therapy assessment and to enhance the value proposition for its existing and prospective customers.
Helmy Eltoukhy, Guardant Health Chairman and co‑CEO, said the expansion “creates an end‑to‑end monitoring test built on the Infinity Smart Platform that simplifies clinical workflows and empowers providers to make faster, more informed decisions with just a simple blood draw.”
Guardant’s Q3 2025 results, which saw strong revenue growth and a raised full‑year guidance, underscore the company’s confidence in the platform’s monetization potential. The new expansion aligns with that trajectory, reinforcing Guardant’s position as a leader in liquid‑biopsy technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.